Human Liver Model Market By Type (In vitro models, In vivo models, Computational models), By Application (Drug discovery & development, Disease modelling, Regenerative medicine, Educational & training, Others), By Model (2D liver models, 3D liver models), By Technology (3D bioprinting technology, Liver-on-chip technology, Stem cell-based liver models, Computational modelling & simulation), By End-User (Pharmaceutical & biotechnology companies, Academic & research institutions, Hospitals & clinical research centers, Contract research organizations (CROs), Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape the Human Liver Model Market in the coming years?

The Human Liver Model Market accounted for USD 1.41 Billion in 2024 and USD 1.62 Billion in 2025 is expected to reach USD 6.69 Billion by 2035, growing at a CAGR of around 15.2% between 2025 and 2035. The Human Liver Model Market is concentrated on the production and business of artificial or simulated liver models that are sold for medical, research, and educational purposes. Through these models, investigators and healthcare providers can be able to analyze liver physiology, disease, and therapy without the use of only living specimens. They find a lot of applications in pharmaceutical testing and drug toxicity studies, as well as in surgical training to make the processes more accurate and safer. The models may be physical copies, computer-simulating models, or bio-engineered liver tissues with different applications.

They aid in the learning of medical students about the complexities involved in terms of anatomy and other mechanisms associated with the liver by providing a practical learning experience. They are used to carry out experiments on the metabolism of the liver, the development of diseases, and regenerative treatment. Another trend in the market is the ease of invention in 3D printing and with tissue engineering, making models more realistic and useful. These models help to partly eliminate the use of animal testing as an alternative source of prohibiting animal testing. The major users of these products are hospitals, universities, and biotechnology companies.

What do industry experts say about the Human Liver Model market trends?

"Liver toxicity is a leading reason why drugs fail in development. We need tests that are reliable, accurate, and reflect what will happen when patients take a new drug in clinical practice."

• Dr. Robert Fontana, a hepatologist at Michigan Medicine

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Human Liver Model market?

How does the rising prevalence of liver diseases like hepatitis and NAFLD drive the demand for human liver models?

The growing burden of liver diseases, including non-alcoholic fatty liver disease (NAFLD) and hepatitis, is a major market driver of the human liver model market. In India, the prevalence of NAFLD is estimated at 38.6 percent in the adult population, with a higher risk among both urban residents and populations at higher risk. On the same note, hepatitis B virus (HBV) infection prevalence in the general population is estimated to be 3 -4%. These situations cause a great burden of chronic liver diseases, which result in complications, including cirrhosis and hepatocellular carcinoma.

The rising prevalence of these diseases compels better research tools that can be used to unravel their pathogenesis as well as come up with effective therapeutic strategies. Compared to the current animal model, human liver models consisting of 3D liver cultures and liver-on-a-chip systems better simulate human biology of liver biology. They are crucial in the role of drug discovery, testing toxicity, and disease modeling, hence speeding up the discovery of drugs designed to target certain illnesses. Due to the increase in liver diseases as well as a need to employ more efficient and ethical research methods, it is projected that the demand for such models will increase.

In what ways do liver models contribute to safer and more predictive preclinical drug testing?

The role of liver models is critical in improving the efficacy and predictability of preclinical drug testing in the Human Liver Model Market, as liver models can more accurately represent the human liver in research than the common animal model used. Such models, such as 3D liver cultures, including liver-on-a-chip, provide a controlled environment to evaluate drug metabolism, drug toxicity, and interactions at a cellular level. They recreate human liver physiology, making it possible to detect any potential negative effects of drugs early in the drug development process and minimizing the possibility of a failure in late-stage clinical trials.

In addition, incorporation of modern technologies like microfluidics, stem cell corresponds related to hepatocytes as well increases the applicability and dependability of such models. The use of liver is in line with regulatory trends for alternative methods to reduce the use of animals and to increase human-relevant information. To cite an example, the United States Food and Drug Administration (FDA) has become increasingly interested in micro physiological systems, such as liver-on-a-chip devices, in a broader attempt to overhaul or modernize its approach to toxicology testing in order to rely less on animal experiments.

How do the high costs of advanced liver models limit their adoption?

The expensive prices of the advanced liver models in the Human Liver Model Market serve as a fundamental limiting factor, thus restricting the market. Advanced platforms like 3D bio-printed lake tissues, organoids, and liver-on-a-chip necessitate considerable investment in specialized equipment and supplies, and personnel. Such costs limit the ability of smaller research institutions, startups, and academic laboratories to obtain and utilize such models.

Also, there is a higher maintenance and functional cost of such models in comparison to the conventional in vitro or animal-based models. Complicated processes of designing physiologically relevant liver models further complicate the cost of development, which also makes scale deployment slow. Consequently, a good number of potential users might stick to the traditional ways of doing which are limited. The said financial barrier has also taken a toll in the case of emerging markets, where investments in advanced biomedical research are not as strong. The main issue is that the cost aspect limits the ability to popularize advanced liver models due to their high cost factor, which inhibits the growth of the market.

What benefits arise from collaborations between biotech firms and academic institutions?

Collaborations between biotech companies and academic research are a large source of growth and innovation in the Human Liver Model Market. Through such collaborations, expertise, resources, and state-of-the-art research facilities can be shared that will speed the creation of more precise and practical liver models. Academic institutions bring in a profound scientific background, access to innovative technologies, and biotech companies bring in capital, commercialization abilities, and the experience of the industry.

Through these collaborations, specially developed liver models could be developed in the area of drug discovery, disease modeling, and regenerative medicine. They also enable much quicker transferring of lab work to solutions ready to enter the market. Moreover, complex tasks, like reproducing the human liver physiology or simulation rare liver diseases, could be tackled with the collaboration of entities, thus perhaps not feasible by an individual organization. These partnerships offer synergies that will lead to innovation and compression of timelines in development and increased market penetration of human liver models.

How can personalized liver models improve patient-specific drug testing?

A potential opportunity in the Human Liver Model Market is patient-specific drug testing that is possible with personalized liver models. They are generated with the own cells of a patient which are normally obtained based on the stem cells, to generate the tissues of the liver that are highly similar to the individual's physiology and even the genes. This enables investigators and health practitioners to understand the way certain individuals are likely to react to medications, which should make it easier to determine their effectiveness and perhaps any side effects that might occur.

Individualized models improve the accuracy of treatment manipulations and avoid the danger of excluding the generalization of medical components. They are especially useful in situations where a patient has a special liver condition or a rare form of genetic disease where standard testing might not have been sufficient. These models also become helpful in creating individual drug regimens and determining the best dose for individual patients. Incorporating individualized liver models in preclinical trials will not only help pharmaceutical companies hasten drug development but also reduce trials and errors. In sum, the use of patient-specific liver models improves both the relevance, safety, and efficacy of drug testing, which fuels innovation and market growth in the human liver model market.

What are the key market segments in the Human Liver Model industry?

Based on the Type, the Human Liver Model Market is classified into in vitro models, in vivo models, and Computational models. The predominant segment in the human liver model market is the market segment of in vitro models. The popularity of these models is explained by the provision of a controlled environment to research liver functions, drug metabolism, and toxicity, with no ethical issues involved in animal research. Calculations and cell preparations are based on in vitro cell culture models of two and three dimensions (2D and 3D cell cultures) and liver spheroid and organoids and liver-on-a-chip models, which give high reproducibility and manipulation of experimental conditions.

They currently find use in pharmaceutical research when screening drug candidates and predicting the effect of drugs on the human liver at an early stage of development. In vitro models are fairly flexible, as scientists can investigate a particular liver disease in a given liver, e.g., hepatitis or non-alcoholic fatty liver disease. Also, recent developments in stem cell technology and 3D bioprinting technology have increased the realism and utility of such models, such that they are becoming more and more adequate when performing clinical simulations. Their popularity in academia, biotech, and pharmaceutical firms has entrenched their focus as the dominant field in the market.

Based on the Application, the Human Liver Model Market is classified into Drug discovery & development, Disease modelling, Regenerative medicine, and Educational & training. The human liver model market is represented by drug discovery & development being the dominating segment. The reasons why this segment is in the lead are related to the fact that the pharma and biotechnology industries are enamored with liver models as a means of reviewing the power and toxicity of drugs, as well as their metabolism prior to clinical trials. Correct liver models contribute to the early detection of possible adverse effects, which alleviates the possibility of late-stage drug failures and is safe for the patients.

In this segment, both 2D and more advanced 3D liver models, such as organoids and liver-on-a-chip systems, offer extensive use in vitro to mimic the work of the human liver in the body. Their efficiency and cost-effectiveness in the ability to screen numerous drug candidates are the reason why such models cannot be forgotten in the research pipeline. Also, regulatory bodies progressively suggest the use of predictive liver models complementary to preclinical studies, which also increases demand. This area is constantly innovating because its main concern is to create safer and more effective therapies, such as the incorporation of stem cell technology and microfluidic systems.

Which regions are leading the Human Liver Model market, and why?

The North American human liver model market is a key part of the global healthcare and biotechnology markets. It features a strong research infrastructure, substantial investments from pharmaceutical companies, and a focus on medical technology innovation. The US stands out with numerous major academic institutions, biotech startups, and pharmaceutical firms, fostering collaboration in liver research and drug development.

The regulatory climate is favorable, supporting the adoption of cutting-edge technologies like organ-on-a-chip devices and 3D bioprinting. These innovations enable more accurate simulation of liver function, improving drug testing and disease modeling.

The Asia Pacific human liver model market is experiencing rapid growth, driven by significant advances in biotechnology and increased investment in medical research infrastructure. Leading countries such as China, Japan, and India are actively advancing liver disease research by strengthening regulatory systems and boosting scientific funding.

This growth is also fueled by the rising prevalence of liver diseases like hepatitis and non-alcoholic fatty liver disease (NAFLD), which creates a higher demand for sophisticated research tools. There is a clear shift from traditional 2D liver models to more advanced 3D models, including organoids and liver-on-a-chip systems, as they better replicate human liver biology.  

What does the competitive landscape of the Human Liver Model market look like?

Human liver model market exhibits a highly competitive environment, and major industry players such as ATCC, Merck KGaA, ZenBio, Organovo Holdings Inc., BioIVT, InSphero, Emulate Inc., Mimetas and CN Bio Innovations Ltd, and Corning Incorporated are focusing on developing new technologies and strategic partnerships to boost their competitive standings. Firms are plugging in pioneering new liver models to offer more predictive and precise resources in drug discovery and toxicity studies; among such models are liver-on-a-chip platforms, bioprinted 3D engineered tissues.

Research institution-biotechnology company strategic alliances are developing the mainstreaming of science and technology as applied through commercial endeavors. Moreover, the trend in the market has been shifting to personalized medicine, and there are companies developing liver models to more closely emulate human physiology to enhance the relevance of preclinical investigation. Increased incidences of liver diseases in the world are leading to an upsurge in the demand for advanced liver models, which results in companies increasing their product segment, thus penetrating into the regional markets.

Human Liver Model Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Human Liver Model industry?

• In April 2024, CN Bio raised $21 million in Series B funding to capitalize on growing interest in its organ-on-a-chip (OOC) technologies, aiming to reinforce its position in the market.
• In December 2023, CN Bio launched its PhysioMimix assay for non-alcoholic steatohepatitis (NASH) to evaluate the effectiveness of INI-822, a drug developed by Inipharm, highlighting the importance of Organ-on-a-Chip technology in liver disease research and drug development.

Report Coverage:

By Type

• In vitro models
• In vivo models
• Computational models

By Application

• Drug discovery & development
• Disease modelling
• Regenerative medicine
• Educational & training
• Others

By Model

• 2D liver models
• 3D liver models

By Technology

• 3D bioprinting technology
• liver-on-chip technology
• Stem cell-based liver models
• Computational modelling & simulation

By End-User

• Pharmaceutical & biotechnology companies
• Academic & research institutions
• Hospitals & clinical research centers
• Contract research organizations (CROs)
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• ATCC
• Merck KGaA
• AcceGen
• ZenBio, Inc.
• Organovo Holdings Inc.
• BioIVT
• InSphero
• Emulate, Inc.
• Mimetas
• CN Bio Innovations Ltd
• Corning Incorporated
• Cyprotex
• Cellink
• Hurel Corporation
• Cyfuse Biomedical K.K.

Frequently Asked Questions (FAQs)